Physician profile
Kathleen Viola
NPI 1083971436
$39,675.43
in general payments reported to CMS, 2019-2025
30 companies · $6,154 in 2025
The $6,154 reported for 2025 was more than what 91% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2021: $847 · 2022: $10K · 2023: $10K · 2024: $12K · 2025: $6,154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Food and Beverage: $11K · Travel and Lodging: $3,204 · Education: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,400.00 |
| Food and Beverage | $11,390.09 |
| Travel and Lodging | $3,204.36 |
| Education | $453.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $25,437.94 | 2019-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $1,721.52 | 2019-2025 | Rinvoq, Skyrizi |
| Organon LLC | $1,580.58 | 2025 | Vtama |
| Epi Health, LLC | $1,513.78 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $1,132.83 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $1,128.31 | 2021-2025 | |
| Dermavant Sciences, INC. | $982.06 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $897.22 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $728.70 | 2021-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $613.20 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $605.30 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $456.08 | 2022-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $411.97 | 2021-2025 | |
| Pfizer INC. | $393.04 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $363.22 | 2024-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $309.56 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Leo Pharma INC. | $274.12 | 2021-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $245.25 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Amgen INC. | $241.69 | 2021-2024 | Otezla, Enbrel |
| Regeneron Pharmaceuticals, INC. | $136.50 | 2025 | Dupixent |
| Almirall LLC | $107.12 | 2023-2025 | Seysara, Klisyri |
| Janssen Scientific Affairs, LLC | $96.21 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.13 | 2022-2024 | Spevigo |
| Kyowa Kirin, INC. | $72.94 | 2022-2023 | Poteligeo |
| Botanix Sb INC | $38.79 | 2025 | Sofdra |
| Biofrontera INC. | $34.22 | 2021-2025 | |
| Convatec INC. | $24.16 | 2024 | |
| Verrica Pharmaceuticals INC. | $22.74 | 2024 | Ycanth |
| Lnhc, INC | $20.66 | 2025 | Zelsuvmi |
| Prugen, INC. Pharmaceuticals | $1.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Viola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.